Serum miR-497-5p serves as a diagnostic biomarker for acute coronary syndrome and predicts the occurrence of major adverse cardiovascular events after percutaneous coronary intervention
Key result
Elevated serum miR-497-5p was an independent predictor of major adverse cardiovascular events during a 6-month follow-up after PCI in patients with ACS (HR 4.773; 95% CI 1.569-12.036; P=0.013).
Why the study?
The study was designed to investigate the diagnostic value of serum miR-497-5p in acute coronary syndrome and its predictive value for major adverse cardiovascular events after percutaneous coronary intervention.
Does serum miR-497-5p level predict the diagnosis of ACS and the occurrence of MACEs after PCI?
Population
110 ACS patients and 82 controls
Comparison
110 ACS patients vs 82 controls
Follow-up
6-month
Authors
Discussion
Loading...
Member takes
Overview
May support ACS diagnosis and post-PCI risk stratification; leaves open prospective validation before clinical use.
Study Design
Type
Observational (n=192)
Structured PICO
Does serum miR-497-5p level predict the diagnosis of ACS and the occurrence of MACEs after PCI?
P
Population
192 participants including 110 patients with acute coronary syndrome and 82 controls, with ACS patients followed for 6 months after percutaneous coronary intervention.
E
Exposure
High serum miR-497-5p levels
C
Comparator
Low serum miR-497-5p levels and healthy controls
O
Outcome
Diagnosis of ACS and occurrence of major adverse cardiovascular events (MACEs) during a 6-month follow-up after PCIcomposite
Main Result
Hazard Ratio: 4.773 (95% CI 1.569–12.036)
p-value: p=0.013
Serum miR-497-5p is a potential diagnostic biomarker for ACS and an independent predictor of MACEs at 6 months following PCI.
Cite This Study
Chen et al. (2022) conducted an observational in Acute coronary syndrome (n=192). Elevated serum miR-497-5p vs. Low serum miR-497-5p / Controls was evaluated on Major adverse cardiovascular events (MACEs) (HR 4.773, 95% CI 1.569-12.036, p=0.013). Elevated serum miR-497-5p was an independent predictor of major adverse cardiovascular events during a 6-month follow-up after PCI in patients with ACS (HR 4.773; 95% CI 1.569-12.036; P=0.013).